Persister M. leprae after introductory rifampicin followed by dapsone therapy.
Lepromatous patients of "Introductory Rifampicin therapy' (Lepr. India, 50: 1978) who received 300 mg Rifampicin daily for 3 months followed by 50-100 mg DDS daily for another 21 months are investigated for persisters in the skin. Mouse foot pad results revealed that at the end of 2 years of treatment viable M. leprae are still persisting in 3 out of 6 patients.